News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
FDA Issues Health Advisory on Pfizer Inc.'s Chantix Tablets
February 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON -- The Food and Drug Administration said it is "increasingly likely" that Pfizer Inc.'s smoking-cessation drug Chantix may be tied to serious psychiatric symptoms. The FDA's comment is part of a public health advisory issued Friday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Pfizer
MORE ON THIS TOPIC
FDA
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
November 2, 2026
·
2 min read
·
Heather McKenzie
Manufacturing
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
October 29, 2026
·
2 min read
·
Nick Paul Taylor
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
·
4 min read
·
Heather McKenzie